NCT06988423View on ClinicalTrials.gov

Evaluation of the Potential Impact of a High-fat Meal on the Pharmacokinetics of CRS3123 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 9, 2025

Primary Completion Date

June 4, 2025

Study Completion Date

June 4, 2025

Conditions
Food Effect in Healthy Participants
Interventions
DRUG

CRS3123 200 mg capsule

CRS3123 200 mg capsule given as a single oral dose

Trial Locations (1)

33136

Syneos Health Miami, Miami

Sponsors

Lead Sponsor

Crestone, Inc
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Crestone, Inc

INDUSTRY